Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China.

Primary efficacy endpoint The change in adjusted mean QMG score from baseline to week 24 was larger in patients receiving tacrolimus versus placebo (–4.9 versus –3.3, respectively) ( Figure 2 ), but the difference did not reach statistical significance [least squares (LS) mean difference: –1.7; 95% CI: –3.5 to 0.1; p = 0.067).

also in 111,027 other papers